Keros Therapeutics (NASDAQ: KROS) reported Q4 EPS of ($1.34), $1.34 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $140 thousand versus the consensus estimate of $0 .

For earnings history and earnings-related data on Keros Therapeutics (KROS) click here.